Start here if you're new
what it is
Larimar is a biotech trying to treat rare diseases with one lead drug and a peptide delivery platform.
how it gets paid
Last year Larimar Therapeutics made n/a in revenue. CTI-1601 lead program was the main engine at $0M, or 100% of sales.
what just happened
Larimar lost $0.45 a share last quarter and still has no sales.
At a glance
B balance sheet — gets the job done, barely
45/100 earnings predictability — expect surprises
-$1.32 fy2024 eps est
n/a operating margin
1.35 beta
xvary composite: 48/100 — below average
What they do
Larimar is a biotech trying to treat rare diseases with one lead drug and a peptide delivery platform.
The moat is the cell-penetrating peptide platform, which means a delivery trick that moves drug cargo into cells. That matters because you have 1 lead candidate, CTI-1601, and not a shelf of approved products. If the trick works, you own a platform; if it fails, you own a 65-person lab with $0M revenue.
How they make money
n/a
annual revenue
CTI-1601 lead program
$0M
Cell-penetrating peptide platform
$0M
Other rare-disease fusion proteins
$0M
Corporate / unallocated
$0M
The products that matter
balance sheet reality
cash runway
not disclosed on this page
This missing number matters more than last quarter's sales, because there were no sales. In pre-revenue biotech, runway tells you how many shots management gets before asking you for more capital.
first filter
lead program
nomlabofusp (CTI-1601)
the core thesis
This is the asset carrying the story. If the data improve, the stock stops looking like dead money. If the data fail, the market will not spend much time admiring the rest of the slide deck.
one bet
pipeline depth
everything after the lead asset
thin on this page
Management will talk about optionality. You should ask a harder question: is there a second source of value here, or just a second paragraph in the presentation. Right now this page supports the latter more than the former.
still unproven
Key numbers
$3.51
share price
That is what you pay today. It sits next to a $476M market cap, so the stock is priced like a small biotech with one lead drug.
$476M
market cap
This is the market's price for the whole company. For a pre-revenue biotech, that number is the bet.
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. Operating margin means profit from core business after operating costs. So what: the core business is still far from profit.
1.35
beta
Beta means how hard the stock moves versus the market. So what: LRMR moves about 35% more than the market.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $3M (1% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for LRMR right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Larimar lost $0.45 a share last quarter and still has no sales.
Value Line puts FY2024 EPS at -$1.32. Yahoo Finance shows TTM revenue at $0M. That means the stock trades on clinical updates, not sales.
$0M
revenue
-$0.45
eps
n/a
n/a
the number that mattered
The -$0.45 quarterly EPS matters because a company with $0M revenue lives or dies on trial news and cash.
source: and Yahoo Finance, 2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
Larimar is not facing generic biotech risk. It is facing three specific problems: the lead asset can fail, the clock can outrun the cash, and even good data can still leave you owning a company with a narrow commercial setup.
med
nomlabofusp disappoints
This is a single-asset story in practice. If the lead program misses, there is no diversified revenue base to catch the valuation on the way down.
Impact: if the next important data read underwhelms, a 40–70% reprice is normal territory for this kind of setup.
med
cash burn turns into dilution
The page does not show verified runway. That absence is a risk by itself. If timelines stretch before de-risking milestones arrive, management usually funds the gap with new shares, not a miracle.
Impact: more shares outstanding means each existing share owns less of any future success.
med
good science still produces a smaller stock outcome
Rare-disease programs do not automatically become great stocks. Even with positive data, the ultimate market size, reimbursement path, and launch economics decide how much value survives the journey.
Impact: upside caps out fast if the commercial path looks narrower than investors hoped.
Here is the part you should not forget: low debt is helpful, but it is not the thesis. The thesis is whether nomlabofusp earns Larimar the right to become a real business before shareholders get diluted again.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
cash runway, once disclosed clearly
Here is the thing: this page does not give you verified runway. Until you have that number, every milestone sits inside a financing question.
risk
nomlabofusp stays the whole story
If every update still loops back to one asset, the company is not broadening the thesis. It is just extending it.
calendar
next corporate update
Use the next management update to check whether the language gets more concrete. Milestones beat vague optimism every time.
trend
whether volatility cools after data
A 5 / 100 price stability score says the stock still trades on uncertainty. If the science de-risks, that number should stop looking this ugly.
Analyst rankings
short-term outlook
mixed
target data is thin here. in human-speak, the street does not have a clean shared view worth leaning on.
risk profile
volatile
A 1.35 beta and 5 / 100 price stability tell you the same story two ways. You should expect bigger swings than the market.
chart momentum
catalyst-led
This chart will follow proof points more than smooth technical trends. The stock is reading the lab before it reads the tape.
earnings predictability
45/100
That score is low because the business is still forming. When there is no stable revenue base, the numbers move around with program timing and spend.
source: institutional data
Institutional activity
institutional ownership data for LRMR is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$4
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive